Report Code: A01293 | Pages: 248 | Feb 2023 | 9549 Views | ||
Author(s) : Linu Dash, Tanjeem Shaikh , Onkar Sumant | Tables: 120 | Charts: 64 |
|
Note: Kindly use your official company email id in the form below for better and quick communication.
Also, Please note we do not send marketing emails to you unless you subscribed to for the news settlers, promotion etc.
Loading Table Of Content...
Cardiovascular prosthetic devices are medical devices that are used to replace or supplement damaged or missing heart tissue. These can be used to replace a damaged heart valve, divert blood flow, or assist with cardiac pacing and other functions. The devices are typically implanted by a cardiac surgeon and can have a significant impact on quality of life.
Increase in the number of product launches and product approvals for cardiovascular prosthetic devices and rise in the number of adoption of strategies such as collaboration, acquisition, and partnership by market players drive the market growth. For instance, in September 2021, Abbott Laboratories, pharmaceutical and medical equipment manufacturing company, announced that the U.S. Food and Drug Administration (FDA) has approved Epic Plus and Epic Plus Supra Stented Tissue Valves of the company to improve therapy options for people with aortic or mitral valve disease.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers